Bone and Joint Infection
Conditions
Keywords
prosthetic joint infection, empirical antibiotherapy, acute kidney injury, vancomycin, cefepim, Piperacillin/tazobactam
Brief summary
The empirical use of vancomycin in combination with a broad-spectrum beta-lactam is currently recommended after the initial surgery of prosthetic joint infection (PJI). However, the tolerability of such high-dose intravenous regimens is poorly known. T
Detailed description
The empirical use of vancomycin in combination with a broad-spectrum beta-lactam is currently recommended after the initial surgery of prosthetic joint infection (PJI). However, the tolerability of such high-dose intravenous regimens is poorly known. The empirical antimicrobial therapy of PJI is associated with an important rate of adverse, linked with the use of the vancomycin and the piperacillin-tazobactam combination. Some studies suggest to use vancomycin-cefepime, which remains to be evaluated in PJI.
Interventions
OTHERempirical antibiotherapy
comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
Sponsors
Hospices Civils de Lyon
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Inclusion criteria
* patients having had a prosthetic joint infection and having had a postoperative empirical antibiotherapy with combination of vancomycine and piperacillin-tazobactam or vancomycine and cefepime
Exclusion criteria
* none
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Treatment Failure | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| rate of adverse events | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | Description of adverses events leading to stop the empirical treatment |
| rate of bacteria responsible for infection | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | bacterial epidemiology |
Countries
France
Outcome results
None listed